Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Envision Healthcare and AmSurg chapter 11 restructuring
We are advising the administrative and collateral agent in connection with AmSurg’s restructuring
Coherus BioSciences $57.5 million follow-on offering
The stock is listed on the Nasdaq Global Market
Envision Healthcare chapter 11 restructuring
We are advising the administrative agent and collateral agent in connection with Envision Healthcare's restructuring
Emergent BioSolutions $150 million at-the-market offering
The shares are listed on the NYSE
Forbion European Acquisition combination with enGene
We are advising Forbion European Acquisition on its de-SPAC transaction
Merck $6 billion notes offering
The investment-grade notes offering consists of six tranches
GSK exclusive licensing agreement with Scynexis
We advised GSK on the transaction
Olema Pharmaceuticals $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
TransMedics Group $460 million convertible senior notes offering
The convertible senior notes are due 2028
ACELYRIN $621 million IPO
The stock is listed on the Nasdaq Global Select Market